Application of geniposide used as acetylcholin esterase inhibitor

A technology of acetylcholinesterase and geniposide, applied in the application field of geniposide as an acetylcholinesterase inhibitor

Inactive Publication Date: 2014-06-18
CHONGQING UNIV OF TECH
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But there is no report about the inhibito...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of geniposide used as acetylcholin esterase inhibitor
  • Application of geniposide used as acetylcholin esterase inhibitor
  • Application of geniposide used as acetylcholin esterase inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Capsule preparation method: mix geniposide and sodium starch glycolate, then add sodium lauryl sulfate aqueous solution and carry out wet granulation. The wet material is then dried in a fluid bed, drying tray or other suitable dryer. The dried granules can then be milled to achieve a suitable particle size distribution prior to mixing with the other ingredients. The mixture is then filled into two hard gelatin capsule shells.

[0067] components Content per capsule

[0068] Geniposide 40 mg

[0069] Sodium Lauryl Sulfate 5 mg

[0070] Lactose hydrate 71 mg

[0071] Magnesium stearate 4 mg

[0072] Sodium starch glycolate 80 mg

[0073] Capsules total weight 200 mg.

Embodiment 2

[0075] Capsule preparation method: granulate geniposide and sodium starch glycolate with sodium lauryl sulfate aqueous solution, then dry the wet material in a fluidized bed, drying tray or other suitable dryer, and then grind the dried granules Grind to achieve a suitable particle size distribution before blending with the other ingredients before filling by weight into capsule shells.

[0076] components Content per capsule

[0077] Geniposide 40 mg

[0078] Sodium Lauryl Sulfate 5 mg

[0079] Lactose hydrate 63 mg

[0080] Talc 4 mg

[0081] Colloidal silicon dioxide 4 mg

[0082] Magnesium stearate 4 mg

[0083] Sodium starch glycolate 80 mg

[0084] Capsules total weight 200 mg.

Embodiment 3

[0086] Tablet preparation method: granulate geniposide, sodium starch glycolate and microcrystalline cellulose with an aqueous solution of sodium lauryl sulfate, and then dry the wet material in a fluidized bed, drying tray or other suitable dryer , the dried granules are then milled to achieve a suitable particle size distribution, the mixture is compressed into tablets, and these tablets are coated if necessary.

[0087] components Content per tablet

[0088] Geniposide 40 mg

[0089] Sodium Lauryl Sulfate 6 mg

[0090] Microcrystalline Cellulose 40 mg

[0091] Sodium starch glycolate 60 mg

[0092] Lactose hydrate 49 mg

[0093] Magnesium stearate 5 mg

[0094] Tablets total weight 200 mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of geniposide which is used as an acetylcholin esterase inhibitor in a medicament for treating and preventing diseases with acetylcholin esterase activity abnormity. The invention relates to geniposide which directly inhibits activity of the acetylcholin esterase, inhibits activity of acetylcholin esterase in a cultured nerve cell, and inhibits activity of the acetylcholin esterase in a transgenic animal brain with Alzheimer's disease. The geniposide can bring inhibition effect on the activity of the acetylcholin esterase into play by virtue of the way, but is not limited to the way, and the geniposide possibly has a potential treatment value on the Alzheimer's disease by inhibiting the acetylcholin esterase.

Description

technical field [0001] The present invention relates to a new application of geniposide, in particular to the application of geniposide as an acetylcholinesterase inhibitor. Background technique [0002] Alzheimer's disease (AD) is a common and highly prevalent neurodegenerative disease. With the improvement of living conditions, the incidence of AD is increasing year by year, and it has become the fourth leading cause of death in the elderly after tumor, heart disease and cerebrovascular disease. The clinical features are characterized by persistent cognitive function and learning impairment. Because the pathological features of AD include β-amyloid (β-amyloid, Aβ) aggregation, deposition to form senile plaques, and tau protein overphosphorylation to form neurofibrillary tangles, and another typical pathological feature is a decrease in the level of acetylcholine (Ach), therefore One of the therapeutic strategies for AD is to use acetylcholinesterase (AChE) inhibitors to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P25/28
Inventor 张永兰刘建辉殷菲
Owner CHONGQING UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap